BB BIOTECH: Extraordinary General Meeting concerning capital
BB BIOTECH AG cordially invites its shareholders to attend an Extraordinary General Meeting on September 17, 2007. The Board of Directors of BB BIOTECH AG proposes a further stock redemption program intended to bring about a capital reduction. This capital reduction is a key measure in order to limit the discount of BB BIOTECH stock on a sustained basis and to reduce it further in future. Within the scope of the proposed stock redemption program, it will be possible to redeem up to 10% of equity instruments, i.e. up to 2 250 000 shares, on the SWX Swiss Exchange via a second trading line.
For further information please contact: Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland Anja Stubenrauch or Adrian Brüngger, Tel. +41 44 267 67 00
--- End of Message ---
BB BIOTECH AG Vordergasse 3 Schaffhausen Switzerland
WKN: 888509; ISIN: CH0001441580; Index: SBIOM, IGSP, SLIFE; Listed: Investment Companies in SWX Swiss Exchange;